Vital Therapies reported $20.61M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Biomarin Pharmaceutical BMRN:US $ 494.65M 112.61M
Dynavax Technologies DVAX:US $ 128.24M 45.01M
Enanta Pharmaceuticals ENTA:US $ 52.02M 544K
Epizyme EPZM:US $ 57.33M 2.29M
Insmed INSM:US $ 153.54M 10.6M
Intercept Pharmaceuticals ICPT:US $ 85.12M 13.73M
Mirati Therapeutics MRTX:US $ 182.57M 2.36M
Omeros OMER:US $ 37.44M 2.39M
Regulus Therapeutics RGLS:US $ 7.18M 606K
Revance Therapeutics RVNC:US $ 86.21M 1.27M
Ultragenyx Pharmaceutical RARE:US $ 230.94M 14.37M
United Therapeutics UTHR:US $ 265.1M 89.5M
Vital Therapies VTL:US $ 20.61M 825K
Xoma XOMA:US $ 5.75M 578K